Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2009, p. 3664-3674, Vol. 53, No. 9
0066-4804/09/$08.00+0 doi:10.1128/AAC.01448-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients
Paul O. Gubbins,1*
Jarrett R. Amsden,2
Scott A. McConnell,1,
and
Elias J. Anaissie3
College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas,1 College of Pharmacy, Butler University, Indianapolis, Indiana,2 Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas3
Received 29 October 2008/ Returned for modification 8 February 2009/ Accepted 5 June 2009
The pharmacokinetics and safety of extended-interval dosing of prophylactic liposomal amphotericin B (L-AMB) in peripheral stem cell transplant recipients were evaluated. The patients received L-AMB daily at 1 mg/kg of body weight or weekly at 7.5 mg/kg or received L-AMB as a single dose (15 mg/kg). The buccal mucosal tissue concentrations of L-AMB were measured. Of the 24 patients enrolled, 5 withdrew after the initial dose due to an infusion-related reaction (n = 2) or significant increases in the serum creatinine (Scr) levels (n = 3). Weekly L-AMB dosing (7.5 mg/kg) produced mean plasma concentrations of >0.300 µg/ml for the first 7 days and >0.220 µg/ml for 7 days after the second dose. A single L-AMB dose (15 mg/kg) produced mean plasma concentrations of >0.491 µg/ml for at least 7 seven days. These concentrations are within the range of the MICs reported in the literature for susceptible strains of Candida and are at the lower limits of the MICs for Aspergillus spp. Extended-interval dosing produced buccal mucosal tissue concentrations well in excess of the MICs reported in the literature for susceptible strains of Candida and Aspergillus spp. Infusion-related reactions occurred in 24% of the patients. Baseline and end-of-study Scr, electrolyte (K+, Mg2+, PO4), and serum transaminase levels were similar across the dosage groups. Five (31%) patients met the nephrotoxicity definition prior to completion of the study. Patients in the weekly or single-dose groups experienced nephrotoxicity significantly faster than the patients in the daily dosing cohort. A weekly L-AMB dose (7.5 mg/kg) or a single L-AMB dose (15 mg/kg) produced sufficient concentrations in plasma and highly vascular tissue to warrant further studies of the safety, efficacy, and practicality of the weekly prophylactic administration of L-AMB.
* Corresponding author. Mailing address: Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham #522, Little Rock, AR 72205. Phone: (501) 686-6683. Fax: (501) 296-1168. E-mail: gubbinspaulo{at}uams.edu
Published ahead of print on 22 June 2009.
Present address: Cubist Pharmaceuticals, Inc.
Antimicrobial Agents and Chemotherapy, September 2009, p. 3664-3674, Vol. 53, No. 9
0066-4804/09/$08.00+0 doi:10.1128/AAC.01448-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»